Nasdaq GlobeNewswire

WTOKF - European Karate Championship, ended on Sunday, October 7, 2018 with success


Championship sponsored by HPIL HOLDING

MIDLAND, Mich., Oct. 08, 2018 (GLOBE NEWSWIRE) -- HPIL Holding (the "Company") (OTC PINK: HPIL) is pleased to announce that The European Championship of the World Traditional Okinawa Karate Federation (WOKF) –  successfully concluded on Sunday, October 7, 2018, in Rome, Italy.

All results obtained by athletes at the European Karate Championship-Rome-Italy on 5-7 October 2018, as well as the final nation-wide ranking, will be published shortly in the WTOKF Official Bulletin.

Karate-do is a martial art, and a form of defense, in which the main goal is to train the spirit and body in an energetic and sincere manner to work for the perfection of character through the accumulation of experience throughout the duration of the training.

Ultimately, the real purpose of karate is to educate the younger generations, from children to the elderly, of the positive effects demonstrated over the years in karate.  Age is not a factor and does not matter.

Karate is a competitive sport enjoyed by young and old athletes around the world.

The WTOKF, a world sports entity that has 84 member countries and around 1.2 million practitioners worldwide, works earnestly and abstinently to be eligible to take part in the Summer Olympics in Tokyo, Japan in 2020.

HPIL HOLDING, as Official Sponsor, has been working with the WTOKF to develop joint projects to support the process of training and improving all organizations in the member countries by organizing at a high level the activities specific to this sport (seminars, international Gasshuku, preselection competitions, regional championships, European championships and world championships). HPIL HOLDING and the WTOKF are also jointly developing a Karate Video game for multiple platforms and on the internet broadcast of Karate Tournaments.

Mr. Amersey, President and CEO of HPIL HOLDING, said: "We continue to work seriously to support the WTOKF in the preparation of all the karate-specific activities so that we can achieve the ideal that each sportsman feels when participating in The Tokyo Olympic Games in 2020.”

Mr. Ionel Bara, President of the WTOKF said, "We are happy of our collaboration with HPIL HOLDING, which has shown us over the years a great support in the realization of all our plans, and we are sure that this will continue so to successfully accomplish all our proposed goals.”

Mr. Bara also said: "Together we have the same goal: An aim and a dream for millions of hearts: Karate as an Olympic Sport!”

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

HPIL Holding ( ) is a diversified holding company listed on OTC Markets. HPIL Holding is focused on investing in both private and public companies in differing business sectors. HPIL Holding does not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, acquires various types of businesses. HPIL Holding also evaluates the acquisition of intellectual properties and technologies.

Safe Harbor / Forward-Looking Statements:
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "plan," "potential," "seek," and "intend," among others. These forward-looking statements are based on the Company's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ include, but are not limited to, substantial competition; our possible need for financing; uncertainties of technological changes; and dependence upon third parties. The Company does not undertake an obligation to update or revise any forward-looking statement. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

For more information please contact:

HPIL Holding
Peter Nicosia
Tel:  +1 (248) 750-1015

Source: HPIL Holding
Twitter: Web Site: HPIL Holding  Tel:  +1(248)750-1015

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

IRYStec Signs Representation in Japan with Ryoden21.11.2018 15:00Pressemelding

MONTREAL, Nov. 21, 2018 (GLOBE NEWSWIRE) -- IRYStec Software Inc., the world leader in perceptual display processing technology, announced today that it has signed a representative agreement with Ryoden. Ryoden’s global expansion of its components and software solutions have enabled them to be a prominent electronics supplier in Japan, highly capable of leading IRYStec’s efforts to enter the Japanese automotive and consumer display device markets. “Ryoden’s vast experience and senior level relationships in both the Automotive OEM and tier 1 customer base along with their strong sales and technical presence across the whole of Japan will enable us to grow the adoption of our Perceptual Display Platform technology.”, said Simon Morris, CEO of IRYStec “We can see the need for perceptual display processing technology to enhance the display device experience especially for automotive displays where visibility of the display in sun light can be a safety concern. We are looking forward to gro

Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 201821.11.2018 14:30Pressemelding

WALTHAM, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Evercore ISI HealthCONx Conference on November 28, 2018 at 3:05 p.m. Eastern Time. The presentation will be webcast and accessible through the investor relations section of the Company’s web site, About Minerva Neurosciences Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301,

Valsoft reinforces global car rental management leadership with acquisition of Thermeon Worldwide Limited21.11.2018 13:00Pressemelding

MONTREAL, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Valsoft Corporation Inc. (“Valsoft”), a Montreal-based company that specializes in the acquisition and development of vertical market software businesses, is pleased to announce the acquisition of Thermeon Worldwide Ltd (“Thermeon”), a global industry-leading provider of car rental software headquartered in the UK with regional offices in the United States and Australia. Under the agreement, Valsoft will acquire Thermeon’s assets, including its brand name, CARS+. CARS+ provides the tools to manage the rental process from quotation and accounting to signature capture and credit card processing. CARS+ is used worldwide by most leading multinational brands and trusted local companies, at service counters, in fleet management, accounting, corporate management, and, most importantly, in Web and mobile customer interfaces. Thermeon, which was launched in 1967 under the guidance of Rollo Pickford, celebrated its 50th birthday in 2017. In the early 1

Anima Biotech Named U.S. Deal of the Year Winner at Lifestars™ Life Science Awards20.11.2018 16:17Pressemelding

Award recognizes the transformative potential of Anima’s $1B+ collaboration with Lilly BERNARDSVILLE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that specifically control protein translation, has been named winner of the “U.S. Deal of the Year” award at the 2018 Lifestars AwardsTM. “We are delighted to receive this award, which recognizes the power and potential of our Translation Control Therapeutics platform,” said Yochi Slonim, co-founder and chief executive officer of Anima Biotech. “Our deal with Lilly further validates our approach and our partnering strategy of creating exclusive collaborations around our partners’ chosen targets.” “Lifestars presented a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s a testament to Anima Biotech’s efforts that this year’s judging faculty commended them in this manner,” said Neil Darkes, Co-CEO, LSX Ltd. And Lifestars. The int

Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics20.11.2018 15:00Pressemelding

US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cernostics, developer of next-generation cancer diagnostics and prognostics, announced that it has received a U.S. Patent and a European Notice to Grant for the company’s TissueCypher® Barrett’s Esophagus Assay, adding protection to previously awarded foundational, platform patents granted in 2014. Earlier this month, Cernostics received notification from the European Patent Office that claims will be issued for its patent entitled “Systems and Compositions for Diagnosing Barrett’s Esophagus and Methods for Using the Same.” This notice comes on the heels of a recent issuance of a corresponding U.S. patent (U.S. Patent No. 10,018,631). Cernostics’ recent patent claims relate to the company’s clinical test for predicting disease progression in patients with BE and assessment of the likelihood that BE may fur

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom